Nutriband Inc. develops prescription transdermal pharmaceutical products, with recurring updates centered on its AVERSA abuse-deterrent transdermal technology and a lead abuse-deterrent fentanyl transdermal system. The technology incorporates aversive agents into patches to address abuse, diversion, misuse and accidental exposure involving drugs with abuse potential, including opioids and stimulant drugs.
Company news also covers product distribution activity for kinesiology tapes and mosquito repellent patches, regulatory and intellectual-property steps tied to transdermal products, shareholder meeting matters, and corporate updates involving operating subsidiaries and Nasdaq-listed common stock and warrants.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has announced the pricing of an underwritten public offering of 1,056,000 units at $6.25 per unit, totaling gross proceeds of $6.6 million. This offering will fund the development of its abuse deterrent fentanyl patch incorporating AVERSA technology. Additionally, Nutriband's securities will commence trading on the Nasdaq Capital Market as of October 1, 2021. The company has granted underwriters a 45-day option to purchase additional shares and warrants to cover over-allotments. CEO Gareth Sheridan emphasized the uplisting's potential to enhance corporate visibility.